Epsilon 3 Bio

Developer of peptides and small molecules that stimulate autophagy

placeCambridge, England, United Kingdom calendar_todayFounded 2010 groups1 employees language e3bio.com

Registered entities

Innovation

6 patent families — focus: Human necessities; filing pace dormant. Cited 7 times.

YearFilings
20172
20184

Investor mix

18 investors on record.

Investor typeCountShare
Venture capital317%
Private equity16%
Accelerator & incubator16%
Bank & private debt16%
Other / undisclosed1267%
Coming soon